Sign in
Not yet taking people in United StatesPhase 2

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

Key facts

Who runs it
argenx
Where
Sherman and Tucson, United StatesSee the 2 sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
170 people, planned
Starts
1 Apr 2027
Expected to end
30 Jul 2030
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Efgartigimod PH20 (ARGX-113) SC
  • Placebo PH20 SC
Record updated
22 September 2026

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Is at least 12 years of age
  • Meeting at least the criteria for possible AIE according to the Graus criteria
  • Part A:; Must not have received prior treatment for AIE with PLEX or Ig (participants may have received glucocorticoids); and must not have received PLEX or Ig for any other medical condition in the last 3 months
  • Part B: Either completing Part A, or If directly entering Part B, must have received first-line treatment for AIE (i.e. corticosteroids, PLEX, and/or Ig) and have a CASE score of 3 or higher, or a score of 2 or higher in a single sub-item

Who cannot take part

  • Known anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody positivity
  • Recent major surgery (within 3 months of screening) or intention to have major surgery during the study, except for surgeries for AIE-related teratomas and thymomas
  • History (within 12 months before screening) of current alcohol, drug (including recreational or prescribed cannabinoids), or medication abuse
  • Any medical condition that would interfere with an accurate assessment of clinical symptoms of AIE
  • Psychiatric or cognitive impairment unrelated to AIE

Where in United States

  • Texas Institute for Neurological DisordersSherman, United StatesContact: Laurie LaurieNot yet recruiting
  • Center for NeurosciencesTucson, United StatesContact: Gwendolyn GrabiecNot yet recruiting

About the trial

What the trial wants to find out

The POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, participants will be randomized to receive either efgartigimod SC or placebo; in part C, participants who completed part B will receive efgartigimod SC; in part D, participants who completed part C will be observed after their last dose of efgartigimod SC. If AIE symptoms return, efgartigimod SC treatment may be restarted during this time.

Read full original descriptionShow less

The maximum overall study duration for participants is up to 3 years. More information can be found in clinicaltrials.argenx.com/polaris

The 4 groups in the trial

  • Part A (Open-Label Lead-in Period): Efgartigimod PH20 SCTreatment being tested

    All participants will receive efgartigimod PH20 SC open label for 8 weeks

    Treatment: Efgartigimod PH20 (ARGX-113) SC

  • Part B (Double-blinded treatment period): Efgartigimod PH20 SCTreatment being tested

    Participants will receive efgartigimod PH20 SC for 24 weeks

    Treatment: Efgartigimod PH20 (ARGX-113) SC

  • Part B (Maintenance double-blinded treatment period): Placebo PH20 SCPlacebo, for comparison

    Participants will receive placebo for 24 weeks

    Treatment: Placebo PH20 SC

  • Part C (Open-Label Extension Period): Efgartigimod PH20 SCTreatment being tested

    Participants who complete Part B will receive efgartigimod PH20 SC for 24 weeks

    Treatment: Efgartigimod PH20 (ARGX-113) SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis
Record updated
22 September 2026